Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ROSSARI BIOTECH 2021-22 Annual Report Analysis
Sat, 25 Jun

ROSSARI BIOTECH has announced its results for the year ended March 2022. Let us have a look at the detailed performance review of the company during FY21-22.

ROSSARI BIOTECH Income Statement Analysis

  • Operating income during the year rose 109.1% on a year-on-year (YoY) basis.
  • The company's operating profit increased by 43.3% YoY during the fiscal. Operating profit margins witnessed a fall and stood at 11.9% in FY22 as against 17.3% in FY21.
  • Depreciation charges increased by 110.5% and finance costs increased by 323.0% YoY, respectively.
  • Other income grew by 108.3% YoY.
  • Net profit for the year grew by 20.7% YoY.
  • Net profit margins during the year declined from 11.2% in FY21 to 6.5% in FY22.

ROSSARI BIOTECH Income Statement 2021-22

No. of Mths Year Ending 12 Mar-21* 12 Mar-22* % Change
Net Sales Rs m 7,093 14,830 109.1%
Other income Rs m 92 191 108.3%
Total Revenues Rs m 7,185 15,021 109.1%
Gross profit Rs m 1,231 1,763 43.3%
Depreciation Rs m 228 481 110.5%
Interest Rs m 30 127 323.0%
Profit before tax Rs m 1,064 1,347 26.6%
Tax Rs m 268 386 44.0%
Profit after tax Rs m 796 961 20.7%
Gross profit margin % 17.3 11.9
Effective tax rate % 25.2 28.6
Net profit margin % 11.2 6.5
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



New Research: 2 stocks to buy as Nifty50 heads towards 40,000

ROSSARI BIOTECH Balance Sheet Analysis

  • The company's current liabilities during FY22 stood at Rs 4 billion as compared to Rs 2 billion in FY21, thereby witnessing an increase of 103.7%.
  • Current assets rose 77% and stood at Rs 7 billion, while fixed assets rose 182% and stood at Rs 7 billion in FY22.
  • Overall, the total assets and liabilities for FY22 stood at Rs 14 billion as against Rs 6 billion during FY21, thereby witnessing a growth of 120%.

ROSSARI BIOTECH Balance Sheet as on March 2022

No. of Mths Year Ending 12 Mar-21* 12 Mar-22* % Change
Networth Rs m 4,067 8,019 97.2
 
Current Liabilities Rs m 1,769 3,602 103.7
Long-term Debt Rs m 0 0 0.0
Total Liabilities Rs m 6,448 14,168 119.7
 
Current assets Rs m 3,814 6,749 76.9
Fixed Assets Rs m 2,633 7,419 181.7
Total Assets Rs m 6,448 14,168 119.7
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



ROSSARI BIOTECH Cash Flow Statement Analysis

  • ROSSARI BIOTECH's cash flow from operating activities (CFO) during FY22 stood at Rs 294 million on a YoY basis.
  • Cash flow from investing activities (CFI) during FY22 stood at Rs -3 billion, an improvement of 703.9% on a YoY basis.
  • Cash flow from financial activities (CFF) during FY22 stood at Rs 3 billion, an improvement of 1,287% on a YoY basis.
  • Overall, net cash flows for the company during FY22 stood at Rs 223 million from the Rs -140 million net cash flows seen during FY21.

ROSSARI BIOTECH Cash Flow Statement 2021-22

Particulars No. of months 12 12 % Change
Year Ending Mar-21 Mar-22
Cash Flow from Operating Activities Rs m 478 294 -38.5%
Cash Flow from Investing Activities Rs m -372 -2,989 -
Cash Flow from Financing Activities Rs m -246 2,918 -
Net Cash Flow Rs m -140 223 -
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Current Valuations for ROSSARI BIOTECH

  • The trailing twelve-month earnings per share (EPS) of the company stands at Rs 17.5, an improvement from the EPS of Rs 15.3 recorded last year.
  • The price to earnings (P/E) ratio, at the current price of Rs 858.3, stands at 49.3 times its trailing twelve months earnings.
  • The price to book value (P/BV) ratio at current price levels stands at 5.9 times, while the price to sales ratio stands at 3.2 times.
  • The company's price to cash flow (P/CF) ratio stood at 47.9 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending 12 Mar-21* 12 Mar-22*
Sales per share (Unadj.) Rs 136.6 269.3
TTM Earnings per share Rs 15.3 17.5
Diluted earnings per share Rs 14.5 17.5
Price to Cash Flow x 55.8 47.9
TTM P/E ratio x 71.7 49.3
Price / Book Value ratio x 11.6 8.6
Market Cap Rs m 46,975 69,088
Dividends per share (Unadj.) Rs 0.5 0.5
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Ratio Analysis for ROSSARI BIOTECH

  • Solvency Ratios
  • Current Ratio: The company's current ratio deteriorated and stood at 1.9x during FY22, from 2.2x during FY21. The current ratio measures the company's ability to pay short-term and long-term obligations.

    Interest Coverage Ratio: The company's interest coverage ratio deteriorated and stood at 11.6x during FY22, from 36.6x during FY21. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.

  • Profitability Ratios
  • Return on Equity (ROE): The ROE for the company declined and down at 12.0% during FY22, from 19.6% during FY22. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

    Return on Capital Employed (ROCE): The ROCE for the company declined and down at 18.4% during FY22, from 26.9% during FY21. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

    Return on Assets (ROA): The ROA of the company declined and down at 7.7% during FY22, from 12.8% during FY21. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending 12 Mar-21* 12 Mar-22*
Current ratio x 2.2 1.9
Debtors’ Days Days 74 75
Interest coverage x 36.6 11.6
Debt to equity ratio x 0.0 0.0
Return on assets % 12.8 7.7
Return on equity % 19.6 12.0
Return on capital employed % 26.9 18.4
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



To see how ROSSARI BIOTECH has performed over the last 5 years, please visit here.

ROSSARI BIOTECH Share Price Performance

Over the last one year, ROSSARI BIOTECH share price has moved down from Rs 1,211.9 to Rs 858.3, registering a loss of Rs 353.7 or around 29.2%.

Overall, the S&P BSE SENSEX is up 0.8% over the year.

(To know more, check out historical annual results for ROSSARI BIOTECH and quarterly results for ROSSARI BIOTECH)

Annual Report FAQs

What is the current share price of ROSSARI BIOTECH?

ROSSARI BIOTECH currently trades at Rs 685.3 per share. You can check out the latest share price performance of ROSSARI BIOTECH here...

What was the revenue of ROSSARI BIOTECH in FY22? How does it compare to earlier years?

The revenues of ROSSARI BIOTECH stood at Rs 15,021 m in FY22, which was up 109.1% compared to Rs 7,185 m reported in FY21.

ROSSARI BIOTECH's revenue has grown from Rs 2,863 m in FY18 to Rs 15,021 m in FY22.

Over the past 5 years, the revenue of ROSSARI BIOTECH has grown at a CAGR of 51.3%.

What was the net profit of ROSSARI BIOTECH in FY22? How does it compare to earlier years?

The net profit of ROSSARI BIOTECH stood at Rs 961 m in FY22, which was up 20.7% compared to Rs 796 m reported in FY21.

This compares to a net profit of Rs 655 m in FY20 and a net profit of Rs 457 m in FY19.

Over the past 5 years, ROSSARI BIOTECH net profit has grown at a CAGR of 34.9%.

What does the cash flow statement of ROSSARI BIOTECH reveal?

The cash flow statement is the financial statement that presents the cash inflows and outflows of a company during a given period of time.

This statement is one of the most useful tools for judging a company's liquidity position. The ratios and parameters in this statement helps test a company's financial health.

The cash flow statement of ROSSARI BIOTECH reveals:

  • Cash flow from operations decreased in FY22 and stood at Rs 294 m as compared to Rs 478 m in FY21.
  • Cash flow from investments decreased in FY22 and stood at Rs -2,989 m as compared to Rs -372 m in FY21.
  • Cash flow from financial activity increased in FY22 and stood at Rs 2,918 m as compared to Rs -246 m in FY21.

Here's the cash flow statement of ROSSARI BIOTECH for the past 5 years.

(Rs m)FY18FY19FY20FY21FY22
From Operations236712568478294
From Investments-205-364-1,903-372-2,989
From Financial Activity-47-2921,569-2462,918
Net Cashflow-1651235-140223

What does the Key Ratio analysis of ROSSARI BIOTECH reveal?

Be it the company's profitability, operations effectiveness or utilization of funds, ratio analysis is an important tool which helps in making investment decisions.

The ratio/financial analysis of ROSSARI BIOTECH reveals:

  • Operating profit margins witnessed a fall and stood at 11.9% in FY22 as against 17.3% in FY21.
  • Net profit margins declined from 11.2% in FY21 to 6.5% in FY22.
  • Debt to Equity ratio for FY22 stood at 0.0 as compared to 0.0 in FY21.

Here's the ratio/financial analysis of ROSSARI BIOTECH for the past 5 years.

 FY18FY19FY20FY21FY22
Operating Profit Margin (%)15.715.017.517.311.9
Net Profit Margin (%)10.28.810.911.26.5
Debt to Equity Ratio (x)0.00.00.10.00.0

Read: Latest Annual Report Analysis of ROSSARI BIOTECH

Equitymaster requests your view! Post a comment on "ROSSARI BIOTECH 2021-22 Annual Report Analysis". Click here!